Last reviewed · How we verify
Placebo by mouth
Placebo by mouth is a Small molecule drug developed by Shenzhen Kangning Hospital. It is currently FDA-approved for Used as control in clinical trials across multiple therapeutic areas. Also known as: Starch tablet by mouth.
Placebo produces therapeutic effects through the patient's expectation and belief that treatment is being received, activating endogenous healing mechanisms.
Placebo produces therapeutic effects through the patient's expectation and belief that treatment is being received, activating endogenous healing mechanisms. Used for Used as control in clinical trials across multiple therapeutic areas.
At a glance
| Generic name | Placebo by mouth |
|---|---|
| Also known as | Starch tablet by mouth |
| Sponsor | Shenzhen Kangning Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo effects are mediated by psychological expectation and conditioning, which can activate neurobiological pathways including endogenous opioid release, dopamine signaling, and immune modulation. These effects are particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue. Placebo is not inert but represents a measurable psychobiological phenomenon.
Approved indications
- Used as control in clinical trials across multiple therapeutic areas
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (PHASE3)
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). (PHASE2, PHASE3)
- The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo by mouth CI brief — competitive landscape report
- Placebo by mouth updates RSS · CI watch RSS
- Shenzhen Kangning Hospital portfolio CI
Frequently asked questions about Placebo by mouth
What is Placebo by mouth?
How does Placebo by mouth work?
What is Placebo by mouth used for?
Who makes Placebo by mouth?
Is Placebo by mouth also known as anything else?
What development phase is Placebo by mouth in?
What are the side effects of Placebo by mouth?
Related
- Manufacturer: Shenzhen Kangning Hospital — full pipeline
- Indication: Drugs for Used as control in clinical trials across multiple therapeutic areas
- Also known as: Starch tablet by mouth
- Compare: Placebo by mouth vs similar drugs
- Pricing: Placebo by mouth cost, discount & access